Merck's $5.7 Billion Diabetes Franchise Vulnerable

A retrospective analysis published by the BMJ supports previously published findings that diabetic patients taking drugs which target the incretin system to control their blood sugars are at greater risk for developing pancreatic problems, such as acute pancreatitis and pancreatic cancer. Could certain big pharma manufacturers be vulnerable to a price collapse, should European and U.S. regulators ? whom are now actively reviewing data on adverse events ? move to restrict usage or outright remove these therapies from the market due to questionable safety?

Source: Forbes.com Healthcare News - July 23, 2013 Category: Pharmaceuticals Authors: YCharts Source Type: news